Abstract
Aims. Diffuse large B-cell lymphomas (DLBCL) can be divided into different subgroups (germinal center B-cell-like [GCB] and non-GCB) according to their gene expression profiles. Immunohistochemistry has been proposed as a surrogate for identifying these subgroups, but data about its efficacy in providing prognostic information are conflicting. Methods and results. This study retrospectively analyzed a series of 105 DLBCL, defined as GCB and non-GCB according to CD10, bcl-6, and MUM1 expression. All patients received a first-line anthracycline-based (CHOP-like) chemotherapy. A total of 50 patients (48%) were identified as GCB and 55 (52%) as non-GCB. The overall response rate was 89% (94/105), with 62 (59%) complete response. Disease progressions were equally distributed between the 2 subgroups and were not significantly different (P =.756) considering the primary site of involvement (nodal or extranodal). The median follow-up was 62 months (range 5-126 months). Overall survival at 5 years was not significantly different between the groups (P =.3468) and was 72.3% and 66.6% for GCB and non-GCB, respectively. Conclusion. The results do not support the prognostic value of GCB and non-GCB immunohistochemical categories in DLBCL of both nodal and extranodal origin. Furthermore, a limited number of antigens may be not sufficient to identify the same patterns defined by cDNA microarray. Prospective studies are warranted to address this issue.
| Original language | English |
|---|---|
| Pages (from-to) | 417-424 |
| Number of pages | 8 |
| Journal | International Journal of Surgical Pathology |
| Volume | 19 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Aug 2011 |
Fingerprint
Keywords
- immunohistochemistry
- non-Hodgkin's lymphomas
- prognostic factors
- tissue microarray
ASJC Scopus subject areas
- Anatomy
- Pathology and Forensic Medicine
- Surgery
Cite this
Tissue microarrays in diffuse large B-cell lymphomas : Are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin? / Laszlo, D.; Pruneri, G.; Andreola, G.; Radice, D.; Calabrese, L.; Rafaniello, P. R.; Nassi, L.; Sammassimo, S.; Alietti, A.; Agazzi, A.; Vanazzi, A.; Martinelli, G.
In: International Journal of Surgical Pathology, Vol. 19, No. 4, 08.2011, p. 417-424.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tissue microarrays in diffuse large B-cell lymphomas
T2 - Are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?
AU - Laszlo, D.
AU - Pruneri, G.
AU - Andreola, G.
AU - Radice, D.
AU - Calabrese, L.
AU - Rafaniello, P. R.
AU - Nassi, L.
AU - Sammassimo, S.
AU - Alietti, A.
AU - Agazzi, A.
AU - Vanazzi, A.
AU - Martinelli, G.
PY - 2011/8
Y1 - 2011/8
N2 - Aims. Diffuse large B-cell lymphomas (DLBCL) can be divided into different subgroups (germinal center B-cell-like [GCB] and non-GCB) according to their gene expression profiles. Immunohistochemistry has been proposed as a surrogate for identifying these subgroups, but data about its efficacy in providing prognostic information are conflicting. Methods and results. This study retrospectively analyzed a series of 105 DLBCL, defined as GCB and non-GCB according to CD10, bcl-6, and MUM1 expression. All patients received a first-line anthracycline-based (CHOP-like) chemotherapy. A total of 50 patients (48%) were identified as GCB and 55 (52%) as non-GCB. The overall response rate was 89% (94/105), with 62 (59%) complete response. Disease progressions were equally distributed between the 2 subgroups and were not significantly different (P =.756) considering the primary site of involvement (nodal or extranodal). The median follow-up was 62 months (range 5-126 months). Overall survival at 5 years was not significantly different between the groups (P =.3468) and was 72.3% and 66.6% for GCB and non-GCB, respectively. Conclusion. The results do not support the prognostic value of GCB and non-GCB immunohistochemical categories in DLBCL of both nodal and extranodal origin. Furthermore, a limited number of antigens may be not sufficient to identify the same patterns defined by cDNA microarray. Prospective studies are warranted to address this issue.
AB - Aims. Diffuse large B-cell lymphomas (DLBCL) can be divided into different subgroups (germinal center B-cell-like [GCB] and non-GCB) according to their gene expression profiles. Immunohistochemistry has been proposed as a surrogate for identifying these subgroups, but data about its efficacy in providing prognostic information are conflicting. Methods and results. This study retrospectively analyzed a series of 105 DLBCL, defined as GCB and non-GCB according to CD10, bcl-6, and MUM1 expression. All patients received a first-line anthracycline-based (CHOP-like) chemotherapy. A total of 50 patients (48%) were identified as GCB and 55 (52%) as non-GCB. The overall response rate was 89% (94/105), with 62 (59%) complete response. Disease progressions were equally distributed between the 2 subgroups and were not significantly different (P =.756) considering the primary site of involvement (nodal or extranodal). The median follow-up was 62 months (range 5-126 months). Overall survival at 5 years was not significantly different between the groups (P =.3468) and was 72.3% and 66.6% for GCB and non-GCB, respectively. Conclusion. The results do not support the prognostic value of GCB and non-GCB immunohistochemical categories in DLBCL of both nodal and extranodal origin. Furthermore, a limited number of antigens may be not sufficient to identify the same patterns defined by cDNA microarray. Prospective studies are warranted to address this issue.
KW - immunohistochemistry
KW - non-Hodgkin's lymphomas
KW - prognostic factors
KW - tissue microarray
UR - http://www.scopus.com/inward/record.url?scp=80052391478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052391478&partnerID=8YFLogxK
U2 - 10.1177/1066896909345596
DO - 10.1177/1066896909345596
M3 - Article
C2 - 19793830
AN - SCOPUS:80052391478
VL - 19
SP - 417
EP - 424
JO - International Journal of Surgical Pathology
JF - International Journal of Surgical Pathology
SN - 1066-8969
IS - 4
ER -